Patent details

Basic Information

Publication number:

EP3912640

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

In force

Application number:

EP211806567

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

PHARMACEUTICAL COMPOSITIONS COMPRISING SECUKINUMAB

French Title of Invention:

COMPOSITIONS PHARMACEUTIQUES CONTENANT SECUKINUMAB

German Title of Invention:

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN, DIE SECUKINUMAB ENTHALTEN

SPC Number:

Dates

Filing date:

04/11/2011

Grant date:

05/03/2025

EP Publication Date:

24/11/2021

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

05/03/2025

EP B1 Publication Date:

05/03/2025

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

04/11/2031

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

26/02/2025

 

 

Name:

Novartis AG

Address:

Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Inventor

1

Name:

MPOFU, Shepard

Address:

Switzerland (CH)

2

Name:

THANGAVELU, Karthinathan

Address:

Switzerland (CH)

3

Name:

RICHARDS, Hanno

Address:

Switzerland (CH)

4

Name:

MACHACEK, Matthias

Address:

Switzerland (CH)

Priority

Priority Number:

41053310 P

Priority Date:

05/11/2010

Priority Country:

United States (US)

Classification

IPC classification:

A61K 39/395; C07K 16/24; A61K 31/519;

Publication

European Patent Bulletin

Issue number:

202510

Publication date:

05/03/2025

Description:

Grant (B1)

Annual Fees

Annual Fee Due Date:

01/12/2025

Annual Fee Number:

15

Annual Fee Amount:

213 Euro

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages